Indivior Applauds New York State Legislation to Combat Opioid Crisis for People Suffering from Substance Use Disorder within the New York State and Local Correctional institutions
Richmond, VA, October 27, 2021 - Indivior PLC (LON: INDV) Indivior applauds legislation enacted in New York aimed at increasing evidence-based treatment access for people suffering from substance use disorder (SUD) and opioid use disorder (OUD) within the New York State and local correctional institutions.1
New York’s enactment of Senate Bill S1795, which will take effect February 2022, requires every county jail and state prison in New York to make medication-assisted treatment available to incarcerated individuals suffering from addiction.1 Decades of science shows that providing comprehensive substance use treatment to incarcerated individuals works, reducing both drug use and crime after a person returns to the community.2
Addressing these barriers to treatment is especially important given an estimated 65 percent of incarcerated individuals nationally struggle with substance use disorder, yet only 5 percent of those who need treatment actually receive it.2 Despite the overwhelming evidence in support of medication-assisted treatment, few prisons and jails offer this treatment due in part to stigma, lack of awareness of the benefits of using medications with treatment, and limited treatment capacity and infrastructure.3
“We strongly support expanding access to evidence-based treatment for people struggling with substance use disorder in correctional settings,” said Mark Crossley, Chief Executive Officer, Indivior. “This legislation furthers an equitable and comprehensive public health approach to ensuring individuals have access to the care they need, when they need it, to aid in their recovery journey while incarcerated and upon re-entry into the community when they are between 10 and 40 times more likely to die of an opioid overdose than the general population.”3
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Media Contacts:
UK
Tulchan Communications
+44 207-353-4200
US
Jennifer Ginther
Director, Communications
Mobile: 804-467-1593
Investor Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
References:
1. Governor Hochul Signs Legislation Package to Combat Opioid Crisis. October 7, 2021
https://www.governor.ny.gov/news/governor-hochul-signs-legislation-package-combat-opioid-crisis
2. National Institute on Drug Abuse: Criminal Justice Drug Facts. June 2020.
https://www.drugabuse.gov/publications/drugfacts/criminal-justice
3. Substance Abuse and Mental Health Services Administration: Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings. HHS Publication No. PEP19-MATUSECJS Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration, 2019. https://store.samhsa.gov/product/Use-of-Medication-Assisted-Treatment-for-Opioid-Use-Disorder-in-Criminal-Justice-Settings/PEP19-MATUSECJS
Download the full press release as a pdf.